Veratis Advisors’s Merck MRK Stock Holding History

Veratis Advisors’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$368K	Buy	+2,863	New	+$335K	0.26%	58
2025 Q4	$350K	Buy	+2,878	New	+$270K	0.28%	56

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Veratis Advisors's MRK Position: Q2 2026 in Review

Veratis Advisors opened a new position in Merck (MRK) in Q2 2026: 2,863 shares worth $368K. The stake represents 0.26% of the portfolio and ranks #58 among its holdings. This is a return to the name: Veratis Advisors previously reported a position in MRK as recently as Q4 2025.

Veratis Advisors first reported a position in MRK in Q4 2025 and has held it in 2 quarters since. 3,828 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Veratis Advisors held 2,863 shares of Merck worth $368K as of Q2 2026.
Merck was a new Veratis Advisors position in Q2 2026.
Merck made up 0.26% of Veratis Advisors's portfolio in Q2 2026, its #58 holding.
Veratis Advisors first reported a position in Merck in Q4 2025 and has held it in 2 quarters since.
3,828 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Veratis Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.